LOGIN
Alendronate treatment for fibrous dysplasia, a rare skeletal disorder
December 2016
Alendronate treatment for fibrous dysplasia, a rare skeletal disorder
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of Bone
J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
40 patients (24 adults and 16 children) with fibrous dysplasia (FD) were randomized to either receive alendronate administration in 6-month cycles for 24 months or placebo. The results revealed that in the alendronate group, NTX-telopeptides markers significantly declined at 18 months, however no significant difference in osteocalcin was observed between groups. Furthermore, areal bone mineral den...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.